UnitedHealth Group (UNH) 2025 Earnings Quality Report

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-03-02) + Yahoo Finance

Auditor: Deloitte & Touche LLP — Clean opinion (1 Critical Audit Matter on IBNR)

One-line verdict: UnitedHealth Group had its worst year as a public company in modern memory. Revenue grew 12% to $447.6B but earnings from operations COLLAPSED from $32.3B to $19.0B (-41%), net income fell from $14.4B to $12.1B (-16%), operating margin compressed from 8.1% to 4.2%, and the Medical Care Ratio exploded from 85.5% to 89.1% — a 360 basis point deterioration that management explicitly blames on "pricing trends and patient and member health status assumptions were well-short of the medical cost trends incurred." Operating cash flow fell 19% to $19.7B against a 12% revenue increase — our A3 check, the first of three red flags. Cash of $24.4B (only $1.1B "available for general corporate use") covers 36% of $78.4B in debt, and goodwill plus intangibles of $131.0B equals 139% of stockholders' equity — the second and third red flags. Optum Health posted a $278M operating LOSS, down from $7.77B in operating profit the year before. The Z-Score dropped to 1.37, squarely in the grey zone. The 10-K announces $3.1B in fourth-quarter restructuring charges, a $623M loss-contract reserve for "anticipated future losses in 2026 for certain value-based care businesses," $799M in additional reserves for Change Healthcare cyberattack provider loans that may not collect, and Medicare Advantage membership contraction for 2026. UnitedHealth Group is not broken, but the 2025 10-K is the numerical confession of a bad year.

Four Segments, One Problem: Medical Costs Ran Away

Per the consolidated results table in the MD&A:

Optum Health lost money in 2025. Operating margin went from +7.4% to -0.3% — a $8.0B swing in a single segment. UnitedHealthcare operating margin fell from 5.2% to 2.7%. The only bright spot was Optum Rx, where the company recorded a $1.5B "net gain" from a fourth-quarter portfolio divestiture.

Per the MD&A's explanation: "For 2025, our pricing trends and patient and member health status assumptions were well-short of the medical cost trends incurred, significantly impacting our earnings."

And: "Medical costs increased primarily due to the IRA-driven impacts on Medicare Part D plans, elevated medical cost trend and growth in people served through Medicare Advantage and those with higher acuity needs. The MCR increased as a result of the revenue effects of the Medicare funding reductions, elevated medical cost trend, the member profile of newly added patients under value-based care arrangements, the acceleration of anticipated future losses in 2026 related to certain Optum Health value-based care contracts..."

The Medical Care Ratio: 360 Basis Points of Pain

The MCR deterioration is the primary story. At $447.6B of revenue, a 360 basis point MCR increase is $16.1B of incremental medical cost — almost exactly matching the $13.3B operating income decline. Medical costs grew 19% ($313.9B vs $264.2B) against premium revenue growth of 14%.

The effective tax rate fell to 12.9% because of "tax benefits having significantly more impact due to lower pre-tax income" — a mechanical byproduct of the earnings collapse, not a positive. Without the tax rate drop, net earnings would have been materially lower still.

Q4 2025 Restructuring: $3.1 Billion of Write-downs

Per the MD&A's disclosure of "Net Portfolio Divestitures, Restructuring and Other Actions":

Total Q4 impact: $568M gain – $2.5B charges – $799M provisioning = approximately $2.7B of net Q4 headwinds, of which $623M is explicitly forward-looking ("anticipated future losses in 2026 for certain value-based care businesses"). Management has pre-reserved for 2026 losses in the value-based care book — that is both a signal of troubles ahead and a mechanism that will make 2026 comparisons easier.

Cash Flow: CFFO Fell $4.5B Against Revenue Growth of $47.3B

Per the Sources and Uses of Cash table in MD&A:

Operating cash flow has fallen in each of the last two years — from $29.1B in 2023 to $24.2B in 2024 to $19.7B in 2025. Per the MD&A: "Decreased cash flows provided by operating activities were driven by decreased cash flows from net earnings, partially offset by changes in working capital accounts, the impact of the sale of receivables and the impacts of the Change Healthcare cyberattack in 2024."

Note "the impact of the sale of receivables" — UNH factored receivables in 2025 as a working capital tool. Absent the factoring, CFFO would be lower still.

Free cash flow of $16.1B did not cover dividends ($7.9B) plus buybacks ($5.5B) plus acquisitions ($4.5B) = $17.9B of shareholder/acquisition outflows. UNH cut buybacks from $9B to $5.5B and acquisitions from $13.4B to $4.5B — visible retrenchment.

The screening engine flags A3 (Revenue vs CFFO): "Revenue grew 11.8% but CFFO declined -18.6%." That is the largest A3 divergence in the screening universe for FY2025.

$24.4B Cash — But Only $1.1B "Available for General Corporate Use"

This is the most important balance sheet disclosure in the 10-K. Per the MD&A:

"As of December 31, 2025, our cash, cash equivalent, available-for-sale debt securities and marketable equity securities balances of $74.7 billion included $24.4 billion of cash and cash equivalents (of which approximately $1.1 billion was available for general corporate use), $48.2 billion of debt securities and $2.1 billion of marketable equity securities."

Only $1.1 billion of UNH's $74.7B in liquid assets is available at the parent company level. The rest sits inside regulated insurance subsidiaries where state insurance regulators control dividend flow. Per the 10-K: "Our U.S. regulated subsidiaries received capital infusions, net of dividends, of $535 million" in 2025 — meaning the parent put more money in than it pulled out. In 2024 the parent received net dividends of $9.2B. The flow reversed.

This is why the C4 screening flag (cash vs debt) hits despite $24.4B of cash on the consolidated balance sheet. The parent-level liquidity is $1.1B against a $78.4B debt stack. UNH relies on its commercial paper program and revolvers backstopped by the committed credit facilities. It is investment-grade and can access markets, but the math is tight by insurance holding company standards.

Goodwill and intangibles of $131.0B represent 139% of equity. This is the D1 red flag — goodwill alone exceeds the entire stockholders' equity. UNH's $10-$15B annual acquisition pace has built a balance sheet where tangible net worth is essentially negative. Any impairment in the value-based care businesses (already down-marked through the loss contract reserve) could cascade.

2026 Outlook — Management Pre-Announces Contraction

Multiple MD&A statements telegraph a difficult 2026:

A $623M loss contract reserve for 2026 says management sees the losses coming and is front-loading them into the 2025 numbers.

The 18-Point Screening

F-Score of 1.68 implies 0.88% probability of manipulation. The manipulation risk is low. The operational deterioration is the story.

Key Risks from the 10-K

1. Medical Cost Estimation Risk — The Critical Audit Matter

Deloitte's Critical Audit Matter: "Medical Care Services Incurred but not Reported (IBNR)" — exactly the line item where UNH underestimated costs in 2025 by ~360 basis points of premium.

Per Item 1A Risk Factors: "If we fail to estimate, price for and manage our medical costs or design benefits in an effective manner, the profitability of our risk-based products and services could decline and could materially and adversely affect our results of operations... Premium revenues from risk-based products constitute nearly 80% of our total consolidated revenues... Relatively small differences between predicted and actual medical costs, or utilization rates as a percentage of revenues, have resulted and in the future may result in significant changes in our financial results."

The 2025 results prove the warning — and Deloitte flagging IBNR as the CAM signals the auditor views this as the most judgmental area of the financial statements.

2. Medicare Advantage Rate Pressure

Per the MD&A: "Medicare Advantage rate notices for numerous years have resulted in industry base rates well below the industry forward medical cost trend... the Advanced Notice for 2027 is far below. Additionally, increased medical costs in 2025, which are expected to continue in future periods, have added to the compounding impact of the previous multi-year rate shortfalls creating sustained pressure on the Medicare Advantage program."

3. Change Healthcare Cyberattack Tail

Per the MD&A: "In the fourth quarter of 2025, the Company increased its reserves for net collection expectations associated with provider loans and other customer balances of $799 million." The February 2024 Change Healthcare breach continues to have financial impact 22 months later. Interest-free loans originally issued to stranded providers now face uncertain collectability.

4. Regulatory and Legal Environment

Per Item 1A: "We are subject to extensive government regulation" and face scrutiny from DOJ antitrust investigations (Amedisys acquisition had to be amended), Department of Labor on MA risk adjustment practices, state insurance regulators, and ongoing securities class actions stemming from the 2025 earnings guidance withdrawal.

5. Value-Based Care Execution

Per the MD&A: "Optum Health's fully accountable value-based care businesses have been impacted by Medicare funding reductions and have also seen continued medical cost trend pressures... As a result of increased pricing in response to anticipated care patterns in 2026 and decreased people served through UnitedHealthcare Medicare Advantage offerings, we expect the number of people served under value-based care arrangements to contract."

The $623M loss contract reserve is the financial admission that Optum Health's value-based care contracts are underpriced relative to the cost of care.

6. Regulated Subsidiary Dividend Constraints

From the MD&A: Parent-level cash flows reversed from +$9.2B in 2024 to -$535M in 2025. When the regulated subsidiaries are stretched, the parent's ability to fund buybacks and dividends depends on the commercial paper market and credit facility drawdowns.

Key Financial Trends (3-Year)

Summary

Grade: F. UnitedHealth Group had its worst year as a public company in over a decade, and the 2025 10-K is the numerical confession.

Three red flags are not about accounting manipulation — they're about the operational and structural state of the business:

Important context: This is a grade on earnings QUALITY, not an assessment of UNH's franchise, solvency, or long-term business model. UNH remains the largest health insurer in America, generates meaningful free cash flow, retains investment-grade credit ratings, and has already pre-announced cost reductions through the $2.5B restructuring program. The Z-Score of 1.37 is in the grey zone but not distress — and the Z-Score's balance sheet-heavy formula penalizes health insurers structurally. Deloitte issued an unqualified opinion with a single Critical Audit Matter on IBNR (exactly the line that went wrong in 2025).

The yellow flags are abundant:

What would change our view: MCR stabilizing back toward 85-86%, parent-level liquidity rebuilding, reduced dependence on working capital sales to support CFFO, and visible progress on the 2026 value-based care book.

Read the 10-K. Read Deloitte's CAM on IBNR. Read the 2027 Medicare Advantage Advance Notice. Then decide.

**Disclaimer**: This report is based on UnitedHealth Group's fiscal year 2025 10-K filed with the SEC on March 2, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade F means major red flags were detected that warrant thorough investigation.